In 2026, Shanghai is a global hub for cellular immunotherapy. The best CAR-T therapy hospitals in Shanghai include Shanghai Ruijin Hospital, Shanghai GoBroad Cancer Hospital, and Jiahui International Hospital. These facilities provide international patients with cutting-edge treatments like Fucaso and Relma-cel, often at a CAR-T cell therapy cost in China that is 70% lower than US benchmarks.
Key Facts
- CAR-T therapy in Shanghai costs $60,000—$150,000 USD in 2026 — approximately 70% less than US benchmarks.
- Shanghai Ruijin Hospital reported a 94.4% overall response rate in its novel GPRC5D-targeted CAR-T trials (early 2026), making it arguably the most prestigious hematology center in Asia.
- Shanghai Jiahui International Hospital, a JCI-accredited partner of Massachusetts General Hospital, successfully achieved MRD negativity in a 78-year-old patient within 2 weeks of CAR-T infusion.
- International patients must submit recent PET-CT scans and pathology reports for eligibility review before receiving a medical invitation letter required for visa entry.
- Fudan University Shanghai Cancer Center (FUSCC) is conducting CD70-targeted CAR-T trials for liver cancer, making Shanghai one of the few cities offering solid-tumor CAR-T outside of lymphoma and leukemia.
Table of Contents
Why Choose Shanghai for CAR-T?
Shanghai combines China’s most advanced research institutions with world-class international patient infrastructure. The city offers CAR-T treatments at costs approximately 70% lower than US benchmarks, along with dedicated bilingual coordination at every major center. CAR-T cell therapy was first approved in the United States in 2017 and has since transformed the treatment of relapsed or refractory B-cell malignancies and multiple myeloma.
The Top 5 Hospital Profiles
1. Shanghai Ruijin Hospital (Jiao Tong University)
- Specialty: Complex blood cancers, relapsed Multiple Myeloma, novel GPRC5D-targeted CAR-T
- Notable: 94.4% overall response rate in GPRC5D-targeted CAR-T trials (early 2026); arguably the most prestigious hematology center in Asia. A landmark 2022 study published in the New England Journal of Medicine (PMID 35381195) demonstrated the strong efficacy of GPRC5D-targeted CAR-T in heavily pre-treated myeloma patients, forming the scientific foundation for Ruijin’s ongoing trials
- International services: International Medical Center with bilingual support
- Internal profile: Ruijin Hospital IMC
- External link: ASH 2024 publication — GPRC5D-targeted CAR-T trial data
- Estimated cost: $60,000—$90,000 USD
2. Shanghai GoBroad Cancer Hospital
- Specialty: Dual-target CAR-T (CD19+CD22); precision medicine for leukemia and lymphoma
- Location: Shanghai Pilot Free Trade Zone
- International services: S2 Medical Visa support, English-speaking care coordinators
- Website: GoBroad Healthcare Group
- Estimated cost: $80,000—$120,000 USD
3. Shanghai Jiahui International Hospital
- Specialty: Western-standard inpatient CAR-T with China’s cell manufacturing capacity
- Notable: JCI-accredited; formal partner of Massachusetts General Hospital; supports direct insurance billing; achieved MRD negativity in a 78-year-old patient within 2 weeks
- Internal profile: Jiahui International Hospital
- Website: jiahui.com
- Estimated cost: $100,000—$150,000 USD
4. Fudan University Shanghai Cancer Center (FUSCC)
- Specialty: CAR-T for solid tumors; CD70-targeted trials for liver cancer; GPC3-targeting for gastric and pancreatic cancer
- Notable: Pioneering CAR-T applications beyond lymphoma and leukemia into gastric, pancreatic, and liver cancers
- Internal profile: Fudan University Cancer Center
- Website: shca.org.cn
5. Zhongshan Hospital (Fudan University)
- Specialty: Hypoxia-inducible CAR-T cells for Stage IV gastric cancer; multidisciplinary approach
- Internal profile: Zhongshan Hospital Fudan University
- Website: zs-hospital.sh.cn
Comparing the Cost among the best CAR-T therapy hospitals in Shanghai
| Hospital | Estimated Total Cost (USD) |
|---|---|
| Shanghai Ruijin Hospital | $60,000—$90,000 |
| Shanghai GoBroad Cancer Hospital | $80,000—$120,000 |
| Shanghai Jiahui International Hospital | $100,000—$150,000 |
| Fudan University Shanghai Cancer Center | Available on assessment |
| Zhongshan Hospital (Fudan) | Available on assessment |
| General Shanghai range | $60,000—$150,000 |
Shanghai CAR-T pricing is approximately 70% lower than comparable treatment in the United States. The FDA approved tisagenlecleucel (Kymriah) and axicabtagene ciloleucel (Yescarta) as the foundational commercial CAR-T products, with US list prices exceeding $400,000 — setting the benchmark against which China’s pricing advantage is measured.
How to Apply as an International Patient
International patients must submit recent PET-CT scans, pathology reports, and full medical history to the hospital’s international department for eligibility review. Upon approval, the hospital issues a medical invitation letter required for the S2 Medical Visa application.
For patients considering broader cancer treatment options beyond CAR-T, our Cancer Treatment in China guide covers immunotherapy, surgery, and proton therapy.
Frequently Asked Questions
For current questions about this topic, contact China Care or consult the relevant official provider or authority for up-to-date information.
